Document is current

Article History

Received: 1 September 2025

Accepted: 17 October 2025

First Online: 15 November 2025

Declarations

:

: All authors received honoraria from Roche, Basel, Switzerland while undertaking this study. Roche commissioned Triducive Partners Limited to facilitate the project and analyze the responses to the consensus statements in line with the Delphi methodology. The authors state the following conflicts of interest. Javier Zarranz-Ventura has worked with and received payment from AbbVie, Adverum, Alcon, Alimera Sciences, Bausch + Lomb, Bayer, Brill Pharma, DORC, Esteve, Novartis, Roche, Sandoz, Topcon, and Zeiss. Aude Ambresin has worked with and received payment from AbbVie, Apellis, Astellas, Bayer, Novartis, Optovue, RetinAI, and Roche. Andrew Chang has acted as a consultant and been on advisory boards for Roche, Bayer, Novartis, Alcon, Zeiss, Apellis, Astellas, and Opthea. Christiana Dinah has acted as a consultant and been on advisory boards for Roche, Boehringer Ingelheim, Bayer, AbbVie, Johnson & Johnson, Eyepoint Pharmaceuticals, Ocular Therapeutix, Alimera Sciences, Astellas, and Apellis; has had speaker fees from Roche, Boehringer Ingelheim, Bayer, Topcon Ltd, AbbVie, Apellis, and Astellas; and has had travel and conference support from Roche, Boehringer Ingelheim, and Apellis. Nancy M Holekamp is an employee of Roche, Basel, Switzerland; and has stock or stock options with Roche, Notal Vision, and Nacuity. Jorge Rocha has worked with and received payment from Apellis, Roche, Topcon, Astellas, and Aché. Insaf Saffar is an employee of Roche, Basel, Switzerland. Rishi P Singh has had personal fees from Apellis, Iveric Bio, EyePoint, Regenxbio, Genentech, Bausch +Lomb, Zeiss, Alcon, and Regeneron; and has received research grants from Janssen.

: Ethical approval was not required for this study, as it involved a non-interventional Delphi process with healthcare professionals only, and did not involve patients, vulnerable populations, or the collection of sensitive or personally identifiable data. In accordance with the Governance Arrangements for Research Ethics Committees (GAfREC), paragraph 2.3.3, research involving staff recruited by virtue of their professional role does not require NHS Research Ethics Committee review unless it involves access to confidential information or raises issues of professional performance. All respondents involved in the survey within the study were informed of the research purpose and that their data would remain anonymous. Their consent was assumed through the completion and submission of their survey responses.